ASH 2017 | A novel BTK inhibitor BGB-3111: new data presented at ASH 2017
Constantine Tam
Constantine Tam, MD, from the Peter MacCallum Cancer Centre, Melbourne, Australia tells us about a novel BTK inhibitor, BGB-3111 and how it might compare with existing treatments, such as ibrutinib. Results from three studies on the agent were presented at the ASH 2017 meeting in Atlanta, GA, and Constantine gives us a summary of the data.
Related videos
Venetoclax-resistance conferring mutation in CLL identified
Piers Blombery
Anti-CD19 CAR T-cell therapy in combination with ibrutinib for CLL/SLL
Saar Gill
An exciting era for CAR T-cell therapy
Mohamad Mohty
Ibrutinib combinations for CLL: iLLUMINATE results & more
Carol Moreno
JCAR017 for relapsed/refractory CLL
Tanya Siddiqi
